title: Effect of magnesium oxide on the activity of standard anti-epileptic drugs against experimental seizures in rats.
abstract: OBJECTIVE
  To study the effect of oral magnesium oxide supplementation alone and on the activity of standard anti-epileptic drugs in the animal models of maximal electroshock seizures (MES) and chemically (pentylenetetrazole [PTZ])-induced seizures.
  
  
  METHODS
  Healthy male albino rats were given magnesium oxide (MgO) supplementation orally in various doses (500, 750 and 1000 mg/kg /day) for 4 weeks (day 1 to day 28). On day 0 and day 29, response to MES (180 mA for 0.2 s) was tested 1 h after pre-administration of phenytoin or carbamazepine orally. Similarly, in the other groups, the response to PTZ 40 mg/kg i.p. was tested 1 h after pre-administration of oral sodium valproate.
  
  
  RESULTS
  Oral administration of MgO in a low dose (500 mg/kg) for 4 weeks in healthy rats appears to exert protective effect against MES. High oral doses of MgO (750 and 1000 mg/kg) appear to enhance the activity of phenytoin and carbamazepine in the MES model. MgO supplementation was seen to decrease the latency of PTZ-induced seizures.
  
  
  CONCLUSIONS
  The dose of oral MgO appears to have an inverse relation with the protective effect in MES-induced seizure model. High doses of MgO supplementation given orally appear to enhance the activity of standard anti-epileptic drugs in the MES-induced seizure model.
authors.affiliation: Department of Pharmacology, Bharati Vidyapeeth Medical College, Pune, India.
authors.forename: Priti Pravin
authors.initials: PP
authors.lastname: Dhande
authors.forename: Rajani Shrikant
authors.initials: RS
authors.lastname: Ranade
authors.forename: Balasaheb B
authors.initials: BB
authors.lastname: Ghongane
references.citation: Am Heart J. 1984 Jul;108(1):188-93
references.pmid: 6375330
references.citation: Neurosci Lett. 1990 Sep 4;117(1-2):207-11
references.pmid: 2149747
references.citation: Neuroscience. 1991;43(1):31-4
references.pmid: 1833668
references.citation: Pharmacol Biochem Behav. 1997 Sep;58(1):261-8
references.pmid: 9264101
references.citation: Indian J Physiol Pharmacol. 2000 Jan;44(1):8-23
references.pmid: 10919091
references.citation: Br J Clin Pharmacol. 1996 Nov;42(5):531-43
references.pmid: 8951184
references.citation: Folia Psychiatr Neurol Jpn. 1977;31(4):645-51
references.pmid: 608666
references.citation: Eur Neuropsychopharmacol. 2001 Feb;11(1):61-8
references.pmid: 11226813
references.citation: Magnes Res. 1992 Dec;5(4):303-13
references.pmid: 1296767
references.citation: Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):974-8
references.pmid: 8456911
references.citation: Am J Obstet Gynecol. 2000 Oct;183(4):793-8
references.pmid: 11035315
references.citation: Eur J Pharmacol. 1993 Feb 23;232(1):59-64
references.pmid: 8096188
references.citation: Funct Neurol. 1989 Jul-Sep;4(3):229-34
references.pmid: 2792856
references.citation: J Assoc Physicians India. 1994 Jun;42(6):456-7
references.pmid: 7852227
references.citation: Epilepsia. 1996 Jul;37(7):618-24
references.pmid: 8681893
references.citation: Epilepsy Res. 2001 Jul;46(1):39-44
references.pmid: 11395287
references.citation: Nature. 1984 May 17-23;309(5965):261-3
references.pmid: 6325946